Price$88.43+1.31 (+1.50%)
01:30 PM07:45 PM
News · 26 weeks65-60%
2026-01-182026-07-12
Mix4590d
- SEC Filings15(33%)
- Insider13(29%)
- Other9(20%)
- Earnings4(9%)
- Analyst2(4%)
- Offering2(4%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Celcuity Inc.SCHEDULE 13G - Celcuity Inc. (0001603454) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Celcuity Inc.SCHEDULE 13D/A - Celcuity Inc. (0001603454) (Subject)
- INSIDERFormer 10% owner Baker Bros. Advisors Lp sold $317,750,000 worth of shares (3,100,000 units at $102.50) (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECAmendment: Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K/A - Celcuity Inc. (0001603454) (Filer)
- FDAFDA Approval for REVTORPYK issued to CELCUITY INC..Submission status for CELCUITY INC..'s drug REVTORPYK (ORIG-1) with active ingredient GEDATOLISIB has changed to 'Approval' on 07/14/2026. Application Category: NDA, Application Number: 219908, Application Classification: Type 1 - New Molecular Entity
- SECSEC Form 144 filed by Celcuity Inc.144 - Celcuity Inc. (0001603454) (Subject)
- SECSEC Form 144 filed by Celcuity Inc.144 - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast CancerREVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined with palbociclib and fulvestrant and REVTORPYK combined with fulvestrant reduced the risk of disease progression or death by 76% and 67%, respectively, compared to fulvestrant among patients with PIK3CA wild-type advanced or metastatic breast cancerCelcuity to host webcast and conference call today Tuesday, July 14, 2026, at 5:30 p.m. EDT MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a biotechnology company focused on developing and commercializing targeted therapies f
- INSIDERSEC Form 4 filed by Director Murphy Polly A.4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERSEC Form 4 filed by Director Buller Richard E4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Murphy Polly A. was granted 1,530 shares, increasing direct ownership by 31% to 6,530 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Dalvey David was granted 1,530 shares (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Romp Charles R was granted 1,530 shares, increasing direct ownership by 712% to 1,745 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Furcht Leo was granted 1,530 shares, increasing direct ownership by 14% to 12,530 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Nigon Richard was granted 1,530 shares, increasing direct ownership by 2% to 80,565 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- INSIDERDirector Buller Richard E was granted 1,530 shares (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECCelcuity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form 424B5 filed by Celcuity Inc.424B5 - Celcuity Inc. (0001603454) (Filer)
- SECSEC Form 305B2 filed by Celcuity Inc.305B2 - Celcuity Inc. (0001603454) (Filer)
- INSIDERChief Science Officer Laing Lance G. exercised 1,000 shares at a strike of $9.89, increasing direct ownership by 0.08% to 1,251,000 units (SEC Form 4)4 - Celcuity Inc. (0001603454) (Issuer)
- SECSEC Form FWP filed by Celcuity Inc.FWP - Celcuity Inc. (0001603454) (Subject)
- PRCelcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the "Convertible Notes"). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000. The Company has granted the underwriters of the offering a 30-day option to purchase up to an additional $75,000,000 aggregate principal
- PRCelcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of its convertible senior notes due 2032 (the "Convertible Notes"). The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional $60,000,000 aggregate principal amount of Convertible Notes, solely to cover over-allotments, if any. The Convertible Notes will be general, unsecured, senior obligations
- SECSEC Form 424B5 filed by Celcuity Inc.424B5 - Celcuity Inc. (0001603454) (Filer)
- PRCelcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast CancerGedatolisib plus fulvestrant and palbociclib (the "gedatolisib-triplet") reduced the risk of disease progression or death by 50% vs. alpelisib plus fulvestrant (HR=0.50; 95% CI: 0.37–0.68; p<0.0001). Median progression-free survival ("PFS") was 11.1 months with the gedatolisib triplet versus 5.6 months with alpelisib plus fulvestrantGedatolisib plus fulvestrant (the "gedatolisib-doublet") reduced the risk of disease progression or death by 49% vs. alpelisib plus fulvestrant (HR=0.51; 95% CI: 0.33–0.79; descriptive p=0.0013). Median PFS was 11.3 months with the gedatolisib-doublet versus 5.6 months with alpelisib plus fulvestrantGedatolisib regimens demonstrated robust and durable responses:
CELC FAQ
7 questionsWhat does Celcuity Inc. do?
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis...Where does CELC stock trade?
Celcuity Inc. (CELC) is listed on NASDAQ.What sector and industry is CELC in?
Celcuity Inc. operates in the Health Care sector, Medical Specialities industry.When did Celcuity Inc. go public?
Celcuity Inc. (CELC) completed its IPO in 2017.What are analysts saying about CELC?
Celcuity Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-05-04. Recent price targets range from $2900.00 to $3000.00.What companies are similar to CELC?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CELC side-by-side with any of them on Quantisnow.How can I track CELC on Quantisnow?
Quantisnow aggregates Celcuity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CELC to receive live email and push alerts on every new disclosure.